Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Braces For More Price Cuts As Turkey Eyes Prevention To Tame Soaring Costs

This article was originally published in PharmAsia News

Executive Summary

Turkey paid TL3.5 billion ($1.8 billion) in 2012 on drugs and treatments for cancer patients, a 25% increase over two years that has caused budget pressure and added to shortages of critical oncology medicines, prompting an industry insider to speculate the government will seek more price cuts to contain costs.

You may also be interested in...



Turkey: International Medtechs Demand Stable Pricing And On-Time Payments

Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.


Turkey’s Domestic Vaccine Production Drive Prompts New Partnerships

The Turkish government’s drive to establish domestic manufacturing for vaccines is showing tentative signs of getting off the ground. New partnerships are forming between Turkish and international partners. However, lack of local know-how is hampering progress.

 

Turkey Finally Ups Reimbursement Prices, But Hospital Debts Still Hang Over Medtechs

Late payments of medtech bills by hospitals combined with persistently low reimbursement prices have pushed Turkish device manufacturers to the brink. But after a recent intervention from the industry, the government has finally done something to address industry’s calls for systematic and comprehensive improvement of medtech reimbursement prices.

Topics

UsernamePublicRestriction

Register

SC082659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel